does allulose increase glp-1 Is a Agonist? Evidence and Key Differences Allulose Benefits: Blood Sugar, GLP-1

Phase 1b (CT-388, 24 weeks): Phase 2 (CT-388 up to 24 mg, 48 weeks): GI AEs described as "mild-to-moderate" and "generally consistent with incretin class" Discontinuation due to AEs: 5.9% (vs 1.3% placebo) Weight loss: 22.5% placebo-adjusted at 48 weeks Key characteristics: Phase 1b showed very high absolute GI rates during titration, but these declined substantially during maintenance Phase 2 data showed a much more favorable tolerability profile with a low discontinuation rate of 5.9% The signal-biased design appears to provide sustained receptor activation without desensitization Despite high initial GI rates, very few patients discontinued, suggesting events were transient and manageable Phase 3 (ENITH program) planned for 2026 Bioglutide (NA-931)# Bioglutide is the first oral quadruple receptor agonist (GLP-1, GIP, glucagon, and IGF-1), developed by Biomed Industries

Related Reading Wegovy Shot Can A Genetic Test Show If I Am Predisposed To Metabolic Syndrome Can A Dna Test Show If I Am Prone To High Hba1C Levels Does A Dna Test Reveal If I Am Prone To Gut Infections Or Imbalances Pricing and availability current as of June 2026

When ordered alongside a compounded GLP-1 prescription, the genetic insights can support a more personalized conversation with your healthcare provider about dosing strategy, drug selection, and monitoring priorities

B, nail plate removed showing a normal sterile matrix